A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Registration Number
- NCT02008227
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 \[anti-PD-L1\] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1225
- Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC
- Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens
- Disease progression during or following treatment with a prior platinum-containing regimen for locally advanced, unresectable/inoperable or metastatic NSCLC or disease recurrence within 6 months of treatment with a platinum-based adjuvant/neoadjuvant regimen or combined modality (e.g., chemoradiation) regimen with curative intent
- Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Known active or untreated central nervous system (CNS) metastases
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome
- History of autoimmune disease
- History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted
- Active hepatitis B or hepatitis C
- Prior treatment with docetaxel
- Prior treatment with cluster of differentiation 137 (CD137) agonists, anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA4), anti-programmed death-1 (anti-PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Docetaxel Docetaxel Docetaxel 75 milligrams per meter square (mg/m\^2) was administered via IV infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first. Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody Atezolizumab Atezolizumab 1200 milligrams (mg) was administered via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurs first.
- Primary Outcome Measures
Name Time Method Percentage of Participants Who Died: PP-ITT Baseline until death due to any cause (up to approximately 2.25 years) OS: TC1/2/3 Or IC1/2/3 Subgroup of SP Baseline until death from any cause (approximately 2.87 years) OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
Overall Survival (OS): PP-ITT Baseline until death due to any cause (up to approximately 2.25 years) OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
OS: TC2/3 or IC2/3 Subgroup of SP Baseline until death due to any cause (up to approximately 2.87 years) OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP Baseline until death due to any cause (up to approximately 2.25 years) Percentage of participants who died among TC1/2/3 or IC1/2/3 subgroup of PP-ITT were reported. TC1 = presence of discernible programmed death-ligand 1 (PD-L1) staining of any intensity in \>/=1% and \<5% TCs; TC2: presence of discernible PD-L1 staining of any intensity in \>/=5% and \<50% TCs; TC3 = presence of discernible PD-L1 staining of any intensity in \>/=50% TCs; IC1 = presence of discernible PD-L1 staining of any intensity in ICs covering between \>/=1% and \<5% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma; IC2 = presence of discernible PD-L1 staining of any intensity in ICs covering between \>/=5% and \<10% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma; IC3 = presence of discernible PD-L1 staining of any intensity in ICs covering \>/=10% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma.
OS: TC1/2/3 or IC1/2/3 Subgroup of PP Baseline until death due to any cause (up to approximately 2.25 years) OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
OS: SP-ITT Baseline until death due to any cause (up to approximately 2.87 years) OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
OS: TC3 or IC3 Subgroup of SP Baseline until death due to any cause (up to approximately 2.87 years) OS duration is defined as the difference in time from the date of randomization to the date of death due to any cause. Data for participants who were not reported as having died at the time of analysis were censored at the date they were last known to be alive. Participants who had no post-baseline information were censored at the date of randomization plus 1 day. OS was estimated using KM methodology.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Objective Response as Determined Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years) Objective response is defined as a CR or PR as determined by the Investigator using RECIST v1.1 on 2 consecutive occasions at least 6 weeks apart. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR. No new lesions.
DOR as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years) DOR:Duration from the first tumor assessment that supports the participant's objective response to PD or death due to any cause,whichever occurs first.CR:complete disappearance of all target lesions and non-target disease.All nodes,both target and non-target,must decrease to normal. No new lesions.PR: At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR.Participants who have not experienced PD at the time of analysis were censored at the time of the last tumor assessment.Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day.PD:at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm,progression of existing non-target lesions,or presence of new lesions.DOR was estimated using KM methodology.
Percentage of Participants With Disease Progression (PD) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or Death: PP-ITT Baseline up to PD or Death (up to approximately 2.25 years) PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 millimeters (mm), or presence of new lesions.
Duration of Response (DOR) as Determined by Investigator Using RECIST v1.1: PP-ITT From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years) DOR:Duration from the first tumor assessment that supports the participant's objective response to PD or death due to any cause,whichever occurs first.CR:complete disappearance of all target lesions and non-target disease.All nodes,both target and non-target,must decrease to normal. No new lesions.PR: At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR.Participants who have not experienced PD at the time of analysis were censored at the time of the last tumor assessment.Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day.PD:at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm,progression of existing non-target lesions,or presence of new lesions.DOR was estimated using KM methodology.
EORTC QLQ-C30 Questionnaire Score: GHS Scale Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days) EORTC QLQ-C30 included GHS/QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).
Percentage of Participants With PD as Determined by Investigator Using RECIST v1.1 or Death: TC1/2/3 or IC1/2/3 Subgroup of PP Baseline up to PD or Death (up to approximately 2.25 years) PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.
Progression-Free Survival (PFS) as Determined by Investigator Using RECIST v1.1: PP-ITT Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years) PFS is defined as the time between the date of randomization and the date of first documented PD or death, whichever occurs first. Participants who are alive and have not experienced PD at the time of analysis were censored at the time of the last tumor assessment. Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.
EORTC QLQ Core 30 (C30) Questionnaire Score: Single Items Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days) EORTC QLQ-C30 included global health status (GHS)/quality of life (QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).
EORTC QLQ-LC13 Questionnaire Score: Coughing Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days) QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for coughing.
PFS as Determined by Investigator Using RECIST v1.1: TC1/2/3 or IC1/2/3 Subgroup of PP Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years) PFS is defined as the time between the date of randomization and the date of first documented PD or death, whichever occurs first. Participants who are alive and have not experienced PD at the time of analysis were censored at the time of the last tumor assessment. Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.
Percentage of Participants With Objective Response as Determined Using RECIST v1.1: PP-ITT Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.25 years) Objective response is defined as a complete response (CR) or partial response (PR) as determined by the Investigator using RECIST v1.1 on 2 consecutive occasions at least 6 weeks apart. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\] 10 mm). No new lesions. At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR. No new lesions.
Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms, Using the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire (QLQ) Lung Cancer Supplemental Module 13 (LC13) Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years) (1 Cycle = 21 days) TTD in patient-reported lung cancer symptoms (pain in chest or in arm/shoulder, dyspnea, or cough) was a composite endpoint defined as the time from randomization to the earliest time the participant's scale scores showed a 10 point or greater increase after baseline in any of the symptoms. A \>/=10-point change in the score perceived by participants was considered as clinically significant. The QLQ-LC13 consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. Scale score range: 0 to 100. Higher symptom score = greater degree of symptom severity.
Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) Against Atezolizumab Baseline up to approximately 2.25 years (assessed at predose [Hour {Hr} 0] on Day 1 of Cycles 1, 2, 3, 4, 8, 16, then every 8 cycles up to end of treatment (EOT) [approximately 2.25 years]; 120 days after EOT [approximately 2.25 years] [1 Cycle=21 days]) Maximum Observed Serum Atezolizumab Concentration (Cmax) Predose (Hr 0), 30 minutes (min) post-infusion (infusion duration: 60 min) on Cycle 1 Day 1 (1 Cycle=21 days) Minimum Observed Serum Atezolizumab Concentration (Cmin) Predose (Hr 0) on Day 1 of Cycles 1, 2, 3, 4, 8, 16, 24, 32, EOT (approximately 2.25 years); 120 days after EOT (approximately 2.25 years) (1 Cycle=21 days) EORTC QLQ-LC13 Questionnaire Score: Hemoptysis Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days) QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for hemoptysis.
EORTC QLQ-LC13 Questionnaire Score: Pain in Arm or Shoulder Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days) QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for pain in arm or shoulder.
EORTC QLQ-C30 Questionnaire Score: Functional Subscales Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days) EORTC QLQ-C30 included GHS/QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).
EORTC QLQ-C30 Questionnaire Score: Symptom Subscale Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days) EORTC QLQ-C30 included GHS/QOL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL and functional scales were linearly transformed so each score ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). Symptom scales/items were also linearly transformed so each score ranged 0-100, where higher scores indicate worse symptoms (e.g., more severe/worsened) and lower scores indicate less symptoms (e.g., less severe/improvement).
EORTC QLQ-LC13 Questionnaire Score: Alopecia Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days) QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for alopecia.
EORTC QLQ-LC13 Questionnaire Score: Dysphagia Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days) QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for dysphagia.
EORTC QLQ-LC13 Questionnaire Score: Dyspnea Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD ( Pro Week 6 Pd) (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days) QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for dyspnea.
PFS as Determined by Investigator Using RECIST v1.1: SP-ITT Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years) PFS is defined as the time between the date of randomization and the date of first documented PD or death, whichever occurs first. Participants who are alive and have not experienced PD at the time of analysis were censored at the time of the last tumor assessment. Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day. PD: at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, or presence of new lesions.
EORTC QLQ-LC13 Questionnaire Score: Pain in Chest Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days) QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for pain in chest.
EORTC QLQ-LC13 Questionnaire Score: Peripheral Neuropathy Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days) QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for peripheral neuropathy.
EORTC QLQ-LC13 Questionnaire Score: Pain in Other Parts Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days) QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for pain in other parts.
EORTC QLQ-LC13 Questionnaire Score: Sore Mouth Day 1 of each treatment Cycle up to EOT (up to approximately 2.25 years); 6 week following PD (up to approximately 2.25 years); survival follow-up-1 (up to approximately 2.25 years) (1 Cycle= 21 days) QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy experienced during past 1 week. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, pain in chest, pain in arm or shoulder, pain in other parts. Response range: (1) not at all to (4) very much. Scores for each item were transformed to 0 to 100, where higher symptom score = greater degree of symptoms. Results have been reported for sore mouth.
Percentage of Participants With Objective Response as Determined Using RECIST v1.1: SP-ITT Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years) Objective response is defined as a complete response (CR) or partial response (PR) as determined by the Investigator using RECIST v1.1 on 2 consecutive occasions at least 6 weeks apart. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis less than \[\<\] 10 mm). No new lesions. At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR. No new lesions.
DOR as Determined by Investigator Using RECIST v1.1: SP ITT From first objective response of CR or PR to PD or death due to any cause, whichever occurred first (up to approximately 2.87 years) DOR:Duration from the first tumor assessment that supports the participant's objective response to PD or death due to any cause,whichever occurs first.CR:complete disappearance of all target lesions and non-target disease.All nodes,both target and non-target,must decrease to normal. No new lesions.PR: At least a 30% decrease in the sum of the diameters of all target and all new measurable lesions, taking as reference the baseline sum of diameters, in the absence of CR.Participants who have not experienced PD at the time of analysis were censored at the time of the last tumor assessment.Participants with no post-baseline tumor assessment were censored at the randomization date plus 1 day.PD:at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm,progression of existing non-target lesions,or presence of new lesions.DOR was estimated using KM methodology.
Trial Locations
- Locations (208)
Comprehensive Blood/Cancer Ctr
🇺🇸Bakersfield, California, United States
Roy & Patricia Disney Family Cancer Center
🇺🇸Burbank, California, United States
St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr
🇺🇸Fullerton, California, United States
Kaiser Permanente - Hayward
🇺🇸Hayward, California, United States
Scripps Clinic; Hematology & Oncology
🇺🇸La Jolla, California, United States
North Valley Hem Onc Med Grp; Thomas&Dorothy Leavey Can Ctr
🇺🇸Northridge, California, United States
Pacific Shores Medical Group
🇺🇸Long Beach, California, United States
Univ of Calif, Los Angeles; Hematology/Oncology
🇺🇸Los Angeles, California, United States
Kaiser Permanente - Oakland
🇺🇸Oakland, California, United States
TMPN/ Cancer Care Associates
🇺🇸Redondo Beach, California, United States
Kaiser Permanente - Roseville
🇺🇸Roseville, California, United States
K. Permanente - San Jose
🇺🇸San Jose, California, United States
Coastal Integrative Cancer Care
🇺🇸San Luis Obispo, California, United States
Kaiser Permanente - San Marcos
🇺🇸San Marcos, California, United States
K. Permanente - Santa Clara
🇺🇸Santa Clara, California, United States
Central Coast Medical Oncology
🇺🇸Santa Maria, California, United States
K. Permanente - S. San Fran
🇺🇸South San Francisco, California, United States
Kaiser Permanente - Vallejo
🇺🇸Vallejo, California, United States
K. Permanente - Walnut Creek
🇺🇸Walnut Creek, California, United States
Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)
🇺🇸Jacksonville, Florida, United States
Georgia Cancer Specialists
🇺🇸Atlanta, Georgia, United States
Ingalls Memorial Hospital
🇺🇸Harvey, Illinois, United States
Cancer Treatment Centers of America-Tulsa
🇺🇸Tulsa, Oklahoma, United States
Texas Oncology, P.A. - Tyler; Tyler Cancer Center
🇺🇸Tyler, Texas, United States
Virginia Oncology Associates
🇺🇸Norfolk, Virginia, United States
Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie
🇫🇷Bordeaux, France
Chu Grenoble - Hopital Albert Michallon; Departement de Cancero-Hematologie
🇫🇷Grenoble, France
Centre Jean Bernard; Radiotherapie Chimiotherapie
🇫🇷Le Mans, France
Centre Oscar Lambret
🇫🇷Lille, France
Hopital Nord; Service d'Oncologie Multidisciplinaire et Innovation Thérapeutique
🇫🇷Marseille, France
Hopital Emile Muller;Pneumologie
🇫🇷Mulhouse, France
Hopital Cochin; Unite Fonctionnelle D Oncologie
🇫🇷Paris, France
Hopital Saint Louis; Oncologie Medicale
🇫🇷Paris, France
GH Paris Saint Joseph; Pneumologie
🇫🇷Paris, France
Centre Hospitalier Lyon Sud; Pneumologie
🇫🇷Pierre Benite, France
CH de la region d Annecy
🇫🇷Pringy, France
Hopital de Pontchaillou; Service de Pneumologie
🇫🇷Rennes, France
Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie
🇩🇪Frankfurt, Germany
Helios Klinikum Emil von Behring GmbH
🇩🇪Berlin, Germany
Thoraxklinik Heidelberg gGmbH
🇩🇪Heidelberg, Germany
Asklepios-Fachkliniken Muenchen-Gauting; Onkologie
🇩🇪Gauting, Germany
Lungenklinik Hemer
🇩🇪Hemer, Germany
Fachklinik für Lungenerkrankungen
🇩🇪Immenhausen, Germany
Krankenhaus Merheim Lungenklinik
🇩🇪Köln, Germany
Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie
🇩🇪Regensburg, Germany
Uoa Sotiria Hospital; Oncology
🇬🇷Athens, Greece
Semmelweis Egyetem X; Pulmonologiai Klinika
🇭🇺Budapest, Hungary
University of Pecs, I st Dept of Internal Medicine
🇭🇺Pecs, Hungary
Seconda Universita' Degli Studi; Divsione Di Oncologia Medica
🇮🇹Napoli, Campania, Italy
Azienda Ospedaliero-Uni Ria Di Udine; Dept. Di Oncologia - Padiglione Pennato
🇮🇹Udine, Friuli-Venezia Giulia, Italy
Irccs Ospedale San Raffaele;Oncologia Medica
🇮🇹Milano, Lombardia, Italy
ASST DI MONZA; Oncologia Medica
🇮🇹Monza, Lombardia, Italy
POLICLINICO RODOLICO, U.O. di Oncologia Medica
🇮🇹Catania, Sicilia, Italy
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda
🇮🇹Padova, Veneto, Italy
A.O.U. Integrata Verona - Policlinico G.B. Rossi; Oncologia Medica - Dip. di Medicina
🇮🇹Verona, Veneto, Italy
A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii
🇮🇹Pisa, Toscana, Italy
Aichi Cancer Center Hospital; Respiratory Medicine
🇯🇵Aichi, Japan
National Hospital Organization Kyushu Cancer Center, Thoracic Oncology
🇯🇵Fukuoka, Japan
Okayama University Hospital; Respiratory and Allergy Medicine
🇯🇵Okayama, Japan
Miyagi Cancer Center; Respiratory Medicine
🇯🇵Miyagi, Japan
Kindai University Hospital; Medical Oncology
🇯🇵Osaka, Japan
Saitama Cancer Center; Thoracic Oncology
🇯🇵Saitama, Japan
Waikato Hospital; Dept of Medical Oncology
🇳🇿Hamilton, New Zealand
Hospital Universitario Clínico San Carlos; Servicio de Oncologia
🇪🇸Madrid, Spain
HUG; Oncologie
🇨🇭Geneve, Switzerland
Kantonsspital Baden; Medizinische Klinik, Onkologie
🇨🇭Baden, Switzerland
Chang Gung Medical Foundation - Linkou; Division of Hematology- Oncology
🇨🇳Taoyuan, Taiwan
Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology
🇹🇷Istanbul, Turkey
Kings Mill Hospital
🇬🇧Sutton in Ashfield, United Kingdom
Christie Hospital NHS Trust
🇬🇧Manchester, United Kingdom
AMPM Research Clinic
🇺🇸Miami, Florida, United States
Kaiser Permanente - Franklin; Kaiser Permanente - Lone Tree
🇺🇸Lone Tree, Colorado, United States
St. Mary's Hospital Regional Cancer Center
🇺🇸Grand Junction, Colorado, United States
Azienda Ospedaliera San Giuseppe Moscati
🇮🇹Avellino, Campania, Italy
Azienda Ospedaliera Univ Parma; Dept Oncologia Medica
🇮🇹Parma, Emilia-Romagna, Italy
Istituto Europeo Di Oncologia
🇮🇹Milano, Lombardia, Italy
Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica
🇮🇹Bari, Puglia, Italy
Ospedale San Luca; Oncologia
🇮🇹Lucca, Toscana, Italy
COIBA
🇦🇷Provincia De Buenos Aires, Argentina
Tampere University Hospital; Dept of Oncology
🇫🇮Tampere, Finland
Summit Medical Center
🇺🇸Florham Park, New Jersey, United States
Willamette Valley Cancer Ctr - 520 Country Club
🇺🇸Eugene, Oregon, United States
Comprehensive Cancer Centers of Nevada
🇺🇸Henderson, Nevada, United States
National Cancer Center Hospital East; Thoracic Oncology
🇯🇵Chiba, Japan
National Cancer Center Hospital; Thoracic Medical Oncology
🇯🇵Tokyo, Japan
Tokyo Medical University Hospital; Dept of Surgery
🇯🇵Tokyo, Japan
Oslo Universitetssykehus HF; Radiumhospitalet
🇳🇴Oslo, Norway
Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc
🇹🇭Bangkok, Thailand
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
🇹🇭Bangkok, Thailand
Luckow Pavillion, Valley Hosp; Office of Clinical Trials
🇺🇸Paramus, New Jersey, United States
Instituto de Oncología de Rosario
🇦🇷Rosario, Argentina
ONCOCENTRO APYS; Oncología
🇨🇱Vina Del Mar, Chile
National Hospital Organization Shikoku Cancer Center; Internal Medicine
🇯🇵Ehime, Japan
National Hospital Organization Kinki-Chuo Chest Medical Center; Internal Medicine
🇯🇵Osaka, Japan
National Hospital Organization, Yamaguchi - Ube Medical Center; Oncology Medicine
🇯🇵Yamaguchi, Japan
Hospital Pulido Valente; Servico de Pneumologia
🇵🇹Lisboa, Portugal
City Clinical Onc.
🇷🇺Saint-Petersburg, Russian Federation
Grupo Angeles
🇬🇹Guatemala City, Guatemala
Uni Cattolica Policlinico Gemelli; Oncologia Medica Ist. Medicina Interna
🇮🇹Roma, Lazio, Italy
Kobe City Medical Center General Hospital; Respiratory Medicine
🇯🇵Hyogo, Japan
SBI of Healthcare Samara Regional Clinical Oncology Dispensary
🇷🇺Samara, Russian Federation
Institute for pulmonary diseases of Vojvodina
🇷🇸Sremska Kamenica, Serbia
New England Cancer Specialists
🇺🇸Scarborough, Maine, United States
Shizuoka Cancer Center; Thoracic Oncology
🇯🇵Shizuoka, Japan
Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii
🇵🇱Otwock, Poland
Hospital Geral; Servico de Pneumologia
🇵🇹Coimbra, Portugal
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
Istituto Nazionale per la Ricerca sul Cancro di Genova
🇮🇹Genova, Liguria, Italy
Hyogo Cancer Center; Thoracic Oncology
🇯🇵Hyogo, Japan
IPO do Porto; Servico de Oncologia Medica
🇵🇹Porto, Portugal
Clinic for Pulmonology, Clinical Center of Serbia
🇷🇸Belgrade, Serbia
State Medical Academy; Oncology
🇺🇦Dnipropetrovsk, Ukraine
Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia
🇪🇸Las Palmas de Gran Canaria, LAS Palmas, Spain
Kaiser Permanente - San Francisco (2238 Geary)
🇺🇸San Francisco, California, United States
US Oncology Research at Minnesota Oncology
🇺🇸Minneapolis, Minnesota, United States
University of Minnesota
🇺🇸Minneapolis, Minnesota, United States
Comprehensive Cancer Centers of Nevada - Eastern Avenue
🇺🇸Las Vegas, Nevada, United States
Oncology Hematology West Midwest
🇺🇸Omaha, Nebraska, United States
Aurora Health Care; Patient Centered Research
🇺🇸Milwaukee, Wisconsin, United States
Illinois Cancer Care
🇺🇸Peoria, Illinois, United States
Quincy Medical Group
🇺🇸Quincy, Illinois, United States
Hematology-Oncology; Associates of the Quad Cities
🇺🇸Bettendorf, Iowa, United States
Karmanos Cancer Inst. ; Hudson Webber; Cancer Research Building
🇺🇸Detroit, Michigan, United States
Billings Clinic; Research Center
🇺🇸Billings, Montana, United States
Montana Cancer Specialists
🇺🇸Missoula, Montana, United States
Roswell Park Cancer Inst.
🇺🇸Buffalo, New York, United States
San Juan Oncology Associates
🇺🇸Farmington, New Mexico, United States
New York Oncology Hematology PC - Latham
🇺🇸Clifton Park, New York, United States
Mid Ohio Onc Hematology Inc
🇺🇸Columbus, Ohio, United States
The Methodist Cancer Center
🇺🇸Houston, Texas, United States
Virginia Cancer Specialists, PC
🇺🇸Fairfax, Virginia, United States
Northwest Cancer Specialists - Vancouver
🇺🇸Vancouver, Washington, United States
Northwest Medical Specialties
🇺🇸Tacoma, Washington, United States
Blue Ridge Cancer Care
🇺🇸Roanoke, Virginia, United States
Instituto Medico Rio Cuarto
🇦🇷Córdoba, Argentina
Lkh innsbruck - univ. Klinikum innsbruck - Tiroler landeskrankenanstalten ges.m.b.h.; Innere Medizin
🇦🇹Innsbruck, Austria
Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
🇦🇹Salzburg, Austria
Hospital das Clinicas - UFRGS
🇧🇷Porto Alegre, RS, Brazil
Windsor Regional Cancer Centre
🇨🇦Windsor, Ontario, Canada
Lkh Vöcklabruck; I. Abt. Für Innere Medizin
🇦🇹Vöcklabruck, Austria
Cite de La Sante de Laval; Hemato-Oncologie
🇨🇦Laval, Quebec, Canada
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology
🇨🇦Montreal, Quebec, Canada
Sociedad de Investigaciones Medicas Ltda (SIM)
🇨🇱Temuco, Chile
Bradford Hill Centro de Investigaciones Clinicas; Bradford Hill Centro de Investigaciones Clinicas
🇨🇱Recoleta, Chile
Helsinki University Central Hospital; Dep. of Pulmonary Medicine
🇫🇮Helsinki, Finland
Oulu University Hospital; Oncology
🇫🇮Oulu, Finland
Hopital Jean Minjoz; Pneumologie
🇫🇷Besancon, France
Institut Sainte Catherine
🇫🇷Avignon, France
Centre Francois Baclesse
🇫🇷Caen, France
Centre Hospitalier Intercommunal; Service de Pneumologie
🇫🇷Creteil, France
Hopital Tenon;Pneumologie
🇫🇷Paris, France
Centre Paul Strauss; Oncologie Medicale
🇫🇷Strasbourg, France
Hia Sainte Anne; Pneumologie
🇫🇷Toulon, France
Hopital Larrey; Pneumologie
🇫🇷Toulouse, France
Hopital Foch; Pneumologie
🇫🇷Suresnes, France
Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II
🇩🇪Halle, Germany
University Hospital of Patras Medical Oncology
🇬🇷Patras, Greece
Thermi Clinic; Oncology Clinic
🇬🇷Thermi Thessalonikis, Greece
Tudogyogyintezet Torokbalint
🇭🇺Torokbalint, Hungary
Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica
🇮🇹Aviano, Friuli-Venezia Giulia, Italy
The Cancer Institute Hospital of JFCR, Respiratory Medicine
🇯🇵Tokyo, Japan
National Cancer Center; Medical Oncology
🇰🇷Gyeonggi-do, Korea, Republic of
Samsung Medical Center; Gastroenterology
🇰🇷Seoul, Korea, Republic of
Seoul National University Bundang Hospital; Hematology Medical Oncology
🇰🇷Gyeonggi-do, Korea, Republic of
Seoul National Uni Hospital; Internal Medicine
🇰🇷Seoul, Korea, Republic of
Catharina Ziekenhuis; Dept of Lung Diseases
🇳🇱Eindhoven, Netherlands
Seoul St.Mary's Hospital; Medical Oncology
🇰🇷Seoul, Korea, Republic of
Antonius Ziekenhuis; Dept of Lung Diseases
🇳🇱Nieuwegein, Netherlands
Jeroen Bosch Ziekenhuis
🇳🇱'S Hertogenbosch, Netherlands
Dunedin Hospital
🇳🇿Dunedin, New Zealand
Centro Hemato Oncologico Panama
🇵🇦Panama, Panama
Medical University of Gdansk
🇵🇱Gdansk, Poland
Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii
🇵🇱Warszawa, Poland
Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii; Oddz.Hematologii Pododz.Chemioterapii
🇵🇱Lodz, Poland
Med.-Polonia Sp. z o.o. NSZOZ
🇵🇱Poznan, Poland
N.N.Burdenko Main Military Clinical Hospital; Oncology Dept
🇷🇺Moscow, Russian Federation
Hospital Ramon y Cajal; Servicio de Oncologia
🇪🇸Madrid, Spain
Fundacion Jimenez Diaz; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario Puerta de Hierro; Servicio de Oncologia
🇪🇸Majadahonda, Madrid, Spain
Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología
🇪🇸La Coruña, Spain
Hospital Regional Universitario Carlos Haya; Servicio de Oncologia
🇪🇸Malaga, Spain
Sahlgrenska Universitetssjukhuset, Lungmedicinkliniken
🇸🇪Goeteborg, Sweden
Hospital Universitario 12 de Octubre; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario La Paz; Servicio de Oncologia
🇪🇸Madrid, Spain
Hospital Universitario Miguel Servet; Servicio Oncologia
🇪🇸Zaragoza, Spain
China Medical University Hospital
🇨🇳Taichung, Taiwan
Karolinska Universitetssjukhuset, Solna; Lung Allergikliniken N10:02
🇸🇪Stockholm, Sweden
Universitetssjukhuset Linköping; Lungmedicinkliniken
🇸🇪Linköping, Sweden
Luzerner Kantonsspital; Medizinische Onkologie
🇨🇭Luzern, Switzerland
National Taiwan Uni Hospital; Internal Medicine
🇨🇳Taipei, Taiwan
Taipei Veterans General Hospital; Chest Dept , Section of Thoracic Oncology
🇨🇳Taipei, Taiwan
Izmir Suat Seren Chest Diseases and Surgery Research Hospital
🇹🇷Izmir, Turkey
Chulalongkorn Hospital; Medical Oncology
🇹🇭Bangkok, Thailand
Karkiv Regional Oncology Center
🇺🇦Kharkiv, Ukraine
Uzhgorod Nat. University Central Municip Hosp; Onc Center
🇺🇦Uzhgorod, Ukraine
Diana Princess of Wales Hosp.
🇬🇧Grimsby, United Kingdom
University College London Hospital
🇬🇧London, United Kingdom
Guys and St Thomas NHS Foundation Trust, Guys Hospital
🇬🇧London, United Kingdom
St George's Hospital
🇬🇧London, United Kingdom
Royal Free Hospital
🇬🇧London, United Kingdom
Auckland city hospital; Auckland Regional Cancer Centre and Blood Service
🇳🇿Auckland, New Zealand
Kaiser Permanente Sacramento Medical Center
🇺🇸Sacramento, California, United States
UC Davis; Comprehensive Cancer Center
🇺🇸Sacramento, California, United States
Orlando Health Inc.
🇺🇸Orlando, Florida, United States
Yonsei University Severance Hospital; Medical Oncology
🇰🇷Seoul, Korea, Republic of
Texas Onc-Central Austin CA Ct
🇺🇸Austin, Texas, United States
Rhode Island Hospital
🇺🇸Providence, Rhode Island, United States
Charing Cross Hospital
🇬🇧London, United Kingdom